Skip to content
Agentic OS
Menu

Intelligence / Healthtech / FDA 510(k) Clearances / Ascensia Diabetes Care

Approvalsdevice cleared27 Aug 2026

Ascensia Diabetes Care

27 Aug 2026: Device cleared · CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT GEN Blood Glucose Monitoring System; CONTOUR® NEXT ONE Blood Glucose Monitoring System. Recorded in the openFDA device 510(k) data.

View the source record

Decided
27 Aug 2026
Device
CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT GEN Blood Glucose Monitoring System; CONTOUR® NEXT ONE Blood Glucose Monitoring System
Specialty
Clinical Chemistry
Country
United States
Location
Valhalla, NY
Clearance type
Traditional
510(k) number
K260545
Submitted
2026-02-18
What this signal means

A clearance starts commercialisation: distribution, reimbursement, software and sales hires.

  1. 268 added in the 30 days to 9 Nov 2026.
  2. Cardiovascular leads with 122 clearances, then Radiology (107).
Reach them with AOS

Find the decision makers at Ascensia Diabetes Care

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

More in Clinical Chemistry

FDA 510(k) Clearances

See all

Source: openFDA device 510(k) data, data to 9 Nov 2026. Devices FDA found substantially equivalent and cleared for the US market. Decision dates as published by FDA. AOS shows what the public record says; it does not verify or endorse the company.